Dividend Declaration

Hipgnosis Songs Fund Limited
23 June 2023
 

LEI: 213800XJIPNDVKXMOC11

23 June 2023

 

HIPGNOSIS SONGS FUND LIMITED

 (the "Company" or "Hipgnosis")

 

Interim Dividend Announcement

 

The Board of Hipgnosis, the first UK listed investment company offering investors a pure-play exposure to songs and associated musical intellectual property rights, and its Investment Adviser, Hipgnosis Song Management Limited, are pleased to announce the Company's interim dividend (the 'Dividend') for the period from 1 January to 31 March 2023 in respect of the Ordinary Shares.

 

The Dividend of 1.3125 pence per Ordinary Share will be payable to Shareholders on the register as at 30 June 2023 with an associated ex-dividend date of 29 June 2023 and a payment date of 28 July 2023.

 

For further information please contact:

 

Hipgnosis Song Management

Merck Mercuriadis

Chris Helm

Giles Croot (Media)

Rufina Pavry (Investors)

 

 

 

 

 

+44 (0)20 4542 1511

+44 (0)20 4542 1530

Singer Capital Markets - Joint Corporate Broker

James Moat / James Maxwell / Alex Emslie (Corporate Finance)

Alan Geeves / James Waterlow / Sam Greatrex (Sales) 

+44 (0)20 7496 3000

J.P. Morgan Cazenove - Joint Corporate Broker

William Simmonds / Jérémie Birnbaum (Corporate Finance)

James Bouverat (Sales)

+44 (0)20 7742 4000

RBC Capital Markets - Joint Corporate Broker

Elliot Thomas / Max Avison (Corporate Finance)

Lisa Tugwell / Anastasia Mikhailova (Sales)

+44 (0)20 7635 4000

Ocorian - Company Secretary & Administrator

Lorna Zimny

+44 (0) 28 9693 0222

The Outside Organisation

Alan Edwards / Nick Caley

+44 (0)7711 081 843

All US music publicity enquiries

Fran Defeo

+1 917 767 5255

NOTES TO EDITORS

About Hipgnosis Songs Fund Limited

(www.hipgnosissongs.com)

Hipgnosis, which was founded by Merck Mercuriadis, is a Guernsey registered investment company established to offer investors a pure-play exposure to songs and associated musical intellectual property rights. The Company has raised a total of almost £1.3 billion (gross equity capital) through its Initial Public Offering on 11 July 2018, and subsequent issues in April 2019, August 2019, October 2019, July 2020, September 2020, February 2021 and July 2021. In September 2019, Hipgnosis transferred its entire issued share capital to the Premium listing segment of the Official List of the FCA and to the London Stock Exchange's Premium segment of the Main Market, and in March 2020 became a constituent of the FTSE 250 Index. Since April 2021, the Company has been resident in the UK for tax purposes and is recognised as an investment trust under applicable HMRC regulations.

About Hipgnosis Song Management Limited

 

The Company's Investment Adviser is Hipgnosis Song Management Limited, which was founded by Merck Mercuriadis, former manager of globally successful recording artists, such as Elton John, Guns N' Roses, Morrissey, Iron Maiden and Beyoncé, and hit songwriters such as Diane Warren, Justin Tranter and The-Dream, and former CEO of The Sanctuary Group plc. The Investment Adviser has assembled an Advisory Board of highly successful music industry experts which include award winning members of the artist, songwriter, publishing, legal, financial, recorded music and music management communities, all with in-depth knowledge of music publishing. Members of Hipgnosis Song Management Limited Advisory Board include Nile Rodgers, The-Dream, Giorgio Tuinfort, Starrah, David A. Stewart, Poo Bear, Bill Leibowitz, Ian Montone and Rodney Jerkins.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings